DRI Healthcare Trust manages a portfolio of pharmaceutical royalties, focusing on 18 royalties from 14 products. Key strengths include a solid FFO payout ratio of 27.1%, indicating good cash flow management, and a reasonable distribution yield of 3.70%. However, the price/FFO ratio of 11.55x suggests potential undervaluation despite a modest revenue growth of 6.8% year-over-year. The net margin of 12.5% is relatively low for the sector, raising concerns about profitability. Overall, the company shows promise but faces challenges in margin improvement.
Loading financial metrics...
Negative net income may indicate operational challenges beyond typical REIT depreciation adjustments.
Positive FFO indicates healthy cash generation from property operations.
FFO payout ratio of 27.1% provides comfortable cushion for distribution growth and reinvestment.
Conservative debt-to-assets ratio of 44.9% provides financial flexibility for acquisitions and growth.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2026-Q2 (June 30, 2026)